INTRODUCTION
The rifamycin antibiotics are fermentation products of Streptomyces mediterranei sp. n. (140) which were discovered in 1957. [In early literature, the name "rifomycin" was used. In this review, the term "rifamycin(s)" stands for the whole class of the rifamycins. For structural formulae, see Fig. 5 .] Since rifamycin B, the compound originally isolated, has no antibacterial activity in its own right, they might easily have escaped attention altogether but for the fact that rifamycin B is readily degraded to the very active derivative rifamycin S, which inhibits the growth of grampositive bacteria at concentrations as low as 0.0025 ,ug of antibiotic per ml (145) . Clinically, the rifamycins proved to be a very valuable class of antibiotics, especially for the treatment of tuberculosis, but the naturally occurring compounds had the disadvantage of not being orally active.
In 1963, Prelog and co-workers determined the chemical structure of various rifamycins (122) and opened up the way for the synthesis of a vast number of semisynthetic derivatives. Lepetit and Ciba succeeded in finding orally active compounds, one of which, rifampin, is now in widespread clinical use. (Unfortunately, two generic names exist: rifampin in the U.S., rifampicin elsewhere; trade name of Ciba-Geigy; Rimactane; trade name of Lepetit: Rifadin.) Only in the last few years, however, since Hartmann et al. (53) and Umezawa et al. (171) discovered that the rifamycins inhibited bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase, has the mechanism of action of the rifamycins in bacteria been elucidated. Since this inhibition is highly specific, the rifamycins have become an important tool in the study of RNA biosynthesis and metabolism. Furthermore, the possibility of specifically blocking bacterial RNA synthesis has prompted many investigators to study the general function of the bacterial cell and the viruses depending on it.
Inhibition of bacterial RNA synthesis is, however, not the only effect displayed by this class of antibiotics. Some derivatives of rifamycin have also been reported to inhibit the growth of certain mammalian DNA viruses. Recently, effects on the growth of RNA tumor viruses were observed, and it has been found that some derivatives inhibit the RNA-dependent DNA polymerase of such viruses.
In this review, an attempt is made to describe the various effects of the rifamycins and to evaluate their significance in relation to various biochemical problems.
ACTION ON BACTERIA General Effects of Rifamycins In Vivo and
In Vitro
Early experiments (21, 40, 41) indicated that some rifamycins inhibited the cell-free protein synthesis of Bacillus subtilis. No such effect was evident, however, in a similar system from Escherichia coli (53) or B. stearothermophilus (179) . In intact cells of B. subtilis, Calvori et al. (21) observed that the uptake of uracil was greatly inhibited by some rifamycin derivatives.
Hartmann and co-workers (53), who found that the inhibition of uracil uptake by rifampin was even more pronounced in cells of Staphylococcus aureus, were the first to suggest that the rifamycins might act on RNA synthesis. Experiments in vitro with DNA-dependent RNA polymerase from E. coli clearly demonstrated that this enzyme was inhibited by rifampin concentrations as low as 2 X 10-8 M (0.02 gg/ml) (53, 171, 174) . Similar results have been obtained with RNA polymerase isolated from S. aureus (175) , Micrococcus luteus (156) , B. subtilis (48) , Azotobacter vinelandii (89) , and B. stearothermophilus (127) . In contrast, DNA-directed DNA polymerase from E. coli was not affected even by concentrations of rifampin 5,000 times higher (53). This highly specific action of the rifamycins differs from the specificity of other potent inhibitors of nucleic acid synthesis such as actinomycin, chromomycin, etc. These compounds inhibit both DNA-dependent DNA and RNA synthesis, although to a different extent, by complexing with the DNA template (80) . The rifamycins, however, do not interact with the template but they affect the RNA polymerase directly (174) .
Further in vivo studies with E. coli and B. subtilis clearly indicated that the inhibition of RNA synthesis is the primary action of the rifamycins and that their effect on protein and DNA synthesis is only a consequence of the inhibition of RNA synthesis (86, 87, 126) . In the following subsections, a detailed account of the interactions between bacterial RNA polymerase and rifamycins will be given.
Interaction of Rifamycins with DNA-Dependent RNA Polymerase (EC 2.7.7.6)
Characterization of RNA polymerase. RNA polymerase is the enzyme responsible for the transcription step. With DNA as template, it catalyzes the polymerization of four ribonucleoside triphosphates into RNA molecules and thus transfers the genetic information stored in the very large DNA molecule into relatively small RNA molecules which are used by the cells in various ways. The general equation of the reaction is given in Fig. 1 . RNA polymerase was independently discovered by Hurwitz et al. (63a) , by Stevens (155a) , and by Weiss and Gladstone (180) In the last 2 years, quite a number of exciting new facts concerning RNA polymerase have come to light. One of the most interesting is that RNA polymerase can exert a positive control function on the transcription of DNA (19, 159, 168, 169, 195) . In this review, we will limit ourselves to those aspects of RNA polymerase that are important for the understanding of the mode of action of the rifamycins. Unless otherwise stated, the studies described below are related to the enzyme of E. coli.
Various steps of the RNA polymerase reaction. In bacterial DNA-directed RNA synthesis, the following enzymatic steps can be distinguished (23a (149, 171) . Furthermore, after the formation of an initiation complex by preincubation of enzyme, DNA, and purine triphosphates, chain elongation with all four triphosphates is practically unaffected by rifampin (149) . The drug, therefore, seems to affect the enzyme before chain elongation.
Studies of the initial complex formation between enzyme and DNA in the presence and absence of rifamycins have shown that the antibiotic does not influence this interaction (113, 171) and that the formation of the initial DNAenzyme complex does not yield protection against rifamycin inhibition. However, incubation of the DNA-enzyme-complex at temperatures above 17 C yields a transformed DNA-enzyme complex which now is protected against the action of rifampin (6, 93, 150) . This transformation occurs in the absence of nucleo~ide triphosphates and seems to be related to the DNA melting reaction described for double-stranded DNA (173, 192) . However, not only the DNA but also the enzyme conformation seems to change, since the activation temperature varies with different enzymes (139) .
When using natural templates, such as phage DNA, the transformed DNA-enzyme complex resistant against rifampin has only been obtained in the presence of initiation factor o. Since a is thought to direct RNA polymerase to the genuine initiation (promoter) sites on the DNA molecule, this result has been taken as evidence that only enzyme molecules attached at DNA-promoter sites undergo this transformation and are thus rendered resistant to rifampin (6) . The finding that there are about two orders of magnitude difference between the rate of dissociation of the transformed DNA-enzyme complex and the rate of its inactivation by rifamycin (193) Complex formation of rifamycins with RNA polymerase. In studies of the interaction between RNA polymerase and rifamycins, it has been found that, by simply mixing the free enzyme with the antibiotic, a complex is formed that can be isolated by passage through a Sephadex column (176) . In contrast to the DNA-enzyme complex, the antibiotic-enzyme complex is formed to the same extent at salt concentrations as high as 1 M. Quantitative measurements have shown that 1 mole of holo enzyme (az383'a) binds 1 mole of rifampin (178) . The same amount of antibiotic is bound by the core enzyme (azo'), which is also inhibited to the same degree as the holo enzyme (33, 178) . Thus, it is not o-that binds rifampin. Experiments with isolated subunits have proved that rifampin binds to the i3 subunit (193) . This result has been confirmed by experiments with RNA polymerase from rifamycinresistant cells (see below). The formation of the complex is very rapid: with 1.5 nmoles of enzyme per ml, a threefold excess of rifampin yields 95% of the complex at 0 C in less than 2 min (Fig. 2) . The stability of the complex varies according to the temperature and can be determined by measuring the exchange rate between unlabeled, complexed rifampin and '4C-labeled, free rifampin (176, 178) . Furthermore, during enzyme purification, the stability of the complex diminishes. Whereas a crude enzyme preparation forms a complex with rifampin that is practically stable for 1 hr at 37 C, a complex with a pure enzyme is decomposed to the extent of 90% under the same conditions (Fig. 3) (76) . To find the reason for this resistance, RNA polymerase from totally resistance strains of E. coli and S. aureus have been isolated and tested in respect to their interaction with rifampin. The resistance proved to be due to a modified RNA polymerase that was insensitive to the inhibitory action of rifampin (175) . Concentrations up to 1,000 times higher than those inhibiting a sensitive RNA polymerase showed no effect on the resistant enzymes, whereas actinomycin inhibited both sensitive and resistant enzymes to the same degree (175) . Inactivation of rifamycins by destruction or binding to factors in the mutant extract could be excluded, since in a mixture of sensitive and resistant enzyme a normal inhibition of the sensitive enzyme was found (37) . These experiments validate the conclusion that the rifamycins interact specifically with RNA poly- With B. subtilis it has been discovered (16) that mutants resistant to rifampin in vivo, but with a sensitive RNA polymerase, can be obtained. In this case, resistance is perhaps related to changes in cell permeability. However, no experiments capable of proving this hypothesis have been done.
Whereas a sensitive enzyme forms a very stable complex with the drug, a completely resistant enzyme forms no complex at all (176) . Experiments with partly resistant enzymes obtained from strains selected at low concentrations of rifampin revealed that complex stability and the extent of enzyme inhibition are closely related: the less stable the complex, the less sensitive is the enzyme to the drug ( Fig. 4a and b ). Since conversion to rifamycin resistance is apparently due to a one-step mutation (2, 76) , it seems that rifamycin is bound to a very specific site of the enzyme and that substitution of single amino acids alters this site in such a way that binding (2) .
An interesting property related to rifamycin resistance has been noted in B. subtilis. Mutants have been isolated, which, in a single mutational event, acquire drug resistance and lose the ability to sporulate, although their vegetative growth is not changed. In normal spores, one ( subunit has a molecular weight of only 110,000 as against 155,000 in a vegatative cell. Since in E. coli the ( subunit is involved in the mutation leading to rifamycin resistance, it is argued that, in drugresistant strains of B. subtilis, the (3 subunit must be changed in such a way that it cannot be 294 BACTERIOL. REV.
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21 seems to be crucial for the effects of the rifamycins. (115) and X-ray analysis (17, 90) .
Although the action of the many rifamycin n B can be oxidized and hydrolyzed to derivatives on bacterial RNA polymerase varies S, a naphthoquinone derivative; reduc-quantitatively, there is no evidence to suggest a Is the naphthohydroquinone derivative qualitative difference. Therefore, it seems reason-SV (45, 122, 141-143; for structural able to assume that the mechanism of action on see Fig. 5 ).
RNA polymerase is the same for all derivatives, ain substances possessing greater anti-although many studies have been done with activity, a vast number of semisynthetic rifampin only. This assumption certainly does not s have been prepared. In many cases, apply to the various actions of rifamycin deriva-S or SV was modified by the introduc-tives on viruses, as will be discussed in the section Lbstituents in position 3, which contains on antiviral activities.
aromatic hydrogen (14, 96, 145) . However, even in bacteria some rifamycin the compound most widely used for derivatives seem to have additional effects. Knusel vical and biochemical purposes, is a and co-workers (77) of the naphthohydroquinone ring inhibit the in vitro growth of gram-positive bacteria resistant to rifampin. Although these derivatives inhibit an RNA polymerase isolated from a sensitive strain, they do not affect a resistant enzyme. So it is conceivable that they exert an additional, as yet unknown, effect on the metabolism of grampositive bacteria. This hypothesis is supported by the observation that the mutation rate for resistance against 3-amino derivatives is much smaller than that for rifampin.
Rifamycins as a Tool in Biochemical Studies
The specific inhibition of bacterial DNAdependent RNA polymerase by the rifamycins has been utilized in many studies of RNA metabolism and biosynthesis. A few examples are given below to show how the use of rifamycins has contributed to the understanding of certain biochemical events. The action of rifamycins on bacterial and mammalian viruses will be discussed in a subsequent section.
Quite a number of studies have been done of the stability of messenger RNA (mRNA) by stopping RNA synthesis with rifampin and following the fate of the already synthesized RNA (118, 137, 160) . The great advantage of the rifamycins over actinomycin D is their specific effect on RNA synthesis.
The fact that the rifamycins completely stop RNA synthesis in E. coil has been taken as evidence that at least the : subunit of RNA polymerase is involved in all E. coli RNA syntheses. Studies in vivo have confirmed the in vitro findings that the rifamycins inhibit RNA chain initiation but not chain elongation (35, 56, 108) .
Yanofsky and co-workers have taken these results as the starting point in their experiments on the mRNA transcribed from the tryptophan operon. After the addition of rifampin, the initiation of new mRNA is inhibited immediately. However, elongation of already initiated mRNA was unaffected. Elongation rates could thus be measured and were found to be dependent on growth temperature: at 37 C, the elongation rate was 37 to 45 nucleotides per sec but at 25 C only 16 to 17 nucleotides per sec (133) . Growth rate had practically no effect on the elongation rate (118, 133) . However, the number of active RNA polymerase molecules per cell increased with growth rate, although the fraction of active enzyme engaged in mRNA synthesis was inversely related to growth rate (118) .
The repressor of the tryptophan operon seems to block RNA polymerase from binding to the promotor region, since in the presence of rifampin and after derepression no RNA synthesis occurred (108) . A similar result has been obtained in respect to the repression of phage lambda (55). The kinetics of the inhibition of RNA synthesis in a derepressed culture of E. coli by tryptophan and rifampin are very similar, indicating that the site of tryptophan repression is the same as or close to the site at which rifampin blocks initiation.
In studies of the position of stable RNA cistrons, Pato and Meyenburg (118) suggest that the three cistrons for 16, 23, and 5S RNA are linked, since their results are consistent with the assumption that, after initiation of the 16S RNA cistron, the 23S and 5S RNA cistrons are transcribed in presence of rifampin. In keeping with this interpretation, Doolittle and Pace (35) found, upon analogous use of rifampin, that the 5S RNA is generated from a transcription unit carrying between 13 and 30 times the amount of genetic information necessary for the production of one molecule of 5S RNA.
Mode of Interaction Between Rifamycins and
Bacterial RNA Polymerase Nature of the enzyme-rifamycin complex. The rifamycin-RNA polymerase complex is so stable that the question arises as to the nature of this complex. At first sight, the most plausible explanation of its stability would appear to be that enzyme and antibiotic are linked by a covalent bond. However, the experiments performed with various rifamycin derivatives show that appropriate substitution results in a gradual loss of complex stability ( Fig. 6b; reference 177) . The same gradual decrease of complex stability is observed when enzymes with increasing resistance to rifamycin are tested (Fig. 4b) . In both cases, complex formation proceeds at an equal or slower rate. Yet, if there would be a covalent bond, the reverse would be expected: if owing to steric hindrance the complex were formed more slowly, it would be more stable. Furthermore, although less active rifamycin derivatives do bind to the enzyme, they are readily displaced by more active ones, the rate of displacement being dependent on the temperature (178) . These data thus indicate that the stability of the rifamycin-RNA polymerase complex is not due to a covalent bond but that other forces, such as hydrogen bonds and 7r-7r bond interactions between the naphtoquinone ring and aromatic amino acids of the enzyme, must be involved.
Relation between rifamycin-enzyme complex and enzyme inhibition. In general, the stability of the rifamycin-enzyme complex determines the degree of enzyme inhibition. This applies to the various resistant enzymes (Fig. 4a and b) and to the rifamycin derivatives with changes in the ansa ring ( Fig. 6a and b) . In both cases, the decrease (20) , and plant roots (111, 112) . Coconut nuclei contain two RNA polymerases, one of which is reported to be inhibited by rifampin (99) . This inhibition can be prevented by the addition of a protein factor. Furthermore, in the water mold Blastocladiella emersonii, three RNA polymerase activities were found, one of which is inhibited by high concentrations of rifampin (62) . The data available give no indication of the significance of these inhibitory effects of rifampin. However, it seems clear that, in general, the nuclear RNA synthesis of eukaryotes is not affected by rifamycin.
But RNA synthesis also occurs in certain other cell particles, such as mitochondria and chloroplasts. In many respects, protein synthesis in these particles resembles that of bacteria, and inhibitors such as chloramphenicol, which specifically affect protein synthesis in bacteria but not in the cytoplasma of eukaryotes, do inhibit mitochondrial and chloroplast protein synthesis (7) . The rifamycins would be an ideal tool for testing for similarities between bacterial and mitochondrial or chloroplast RNA polymerases. Quite a number of studies have been undertaken along these lines, but the results obtained thus far do not allow a clear-cut conclusion. The main difficulty seems to be the isolation of a welldefined RNA polymerase whose activity is dependent on DNA.
Tests on intact mitochondria or chloroplasts are not conclusive because of permeation problems. Various authors claim to have obtained enzyme inhibition, but the amounts of rifamycin used are 100 to 1,000 times higher than those needed to inhibit bacterial RNA polymerase. In vivo experiments with green algae have shown (132, 161 ) that rifampin causes bleaching, i.e., impairs the function of chloroplasts. Furthermore, incorporation of 32p into chloroplast RNA is inhibited, and the drug seems to promote the dissociation of chloroplast ribosomes into subunits (15) . Cells that were grown in the presence of rifampin for several generations still contained chloroplasts, although they showed a great deal of internal disorganization and could no longer fix CO2. In vitro RNA synthesis in isolated chloroplasts was inhibited by concentrations of 100 ,g/ml, whereas 50 ug/ml had very little effect (161) . It thus seems clear that rifampin has some effect on chloroplasts; however, the data do not warrant the conclusion that chloroplast RNA polymerase is inhibited by the antibiotic in a way comparable to bacterial RNA polymerase.
In vitro RNA synthesis in swollen mitochondria of yeast and rat liver was not inhibited by con- centrations of rifampin as high as 50 4g/ml, whereas the same concentration of actinomycin caused 90% inhibition (183, 188) . Thus, a permeation effect does not seem likely in this case. An analogous result has been obtained with Neurospora mitochondria (59) . Furthermore, a mitochondrial RNA polymerase from a cytoplasmic "petite" mutant, whose activity was dependent on added DNA, was not affected by rifampin concentrations as high as 16 ,g/ml (184) . Just recently, two forms of mitochondrial RNA polymerase were isolated from Saccharomyces cerevisiae: both were dependent on DNA, but rifampin had no inhibitory effect in concentrations as high as 40 ,g/ml (170), which is more than a 1,000-fold higher concentration than required for the inhibition of bacterial RNA polymerase. On the other hand, there have been some reports which state that rifampin inhibits mitochondrial RNA synthesis in rat liver or bovine heart (44, 47, 146) . Since very high concentrations of the drug were needed in these cases to obtain an effect and since the enzymes used were not well characterized, no definitive conclusion as to the action of rifampin on mammalian mitochondrial RNA synthesis can be drawn. However, the experiments with yeast mitochondrial RNA polymerase do make it clear that the theory that, in general, mitochondrial RNA polymerase is a bacteria-like enzyme cannot be upheld.
ANTIVIRAL ACTIVITIES
Since prokaryotic and eukaryotic cells differ so much in their sensitivity to rifamycin, it is clear that the effects to be expected on the corresponding viruses will likewise be quite different. Any involvement of host bacterial RNA polymerase in phage growth would lead to the inhibition of virus development. Furthermore, the development of bacterial viruses insensitive to rifamycins could conveniently be studied by blocking host RNA synthesis with rifamycin. On the other hand, since mammalian RNA polymerase is insensitive to the antibiotic, the possibility has been raised that the rifamycins might prove to be selective agents against mammalian viruses. In the following sections, the various actions of the rifamycins on bacterial and mammalian viruses will be discussed. 105) , and X (162), has been shown to remain sensitive to the rifamycins throughout phage infection. In drugresistant cells, the phages develop in a normal way even in the presence of the antibiotic. This has been taken as an indication that the rifamycinsensitive part of the host RNA polymerase is required for the transcription of the entire genome. However, studies with phage T7 have revealed that the growth of this virus becomes resistant to rifamycin inhibition after 5 min, coinciding with the appearance of a specific T7 RNA polymerase (23) that is responsible for the transcription of late bacteriophage functions. This enzyme is not affected by rifampin (23, 50) . At least one new phage protein is also directly required for late transcription in both T4 and X (123, 151) . If these proteins were enzymes similar to that found in T7, then the sensitivity to rifamycins of late transcription in the phages could be explained by assuming that host RNA polymerase is required for some other phage functions (23) .
Studies with RNA viruses have demonstrated that the growth of phages such as f2 (39) and Q/3 (66) is not substantially affected by rifampin added 4 to 5 min after infection, although under these conditions host-specific RNA synthesis is inhibited by more than 95%. However, when the drug is added before or shortly after phage infection, the virus development is severely inhibited. No clear explanation for this inhibition has yet been found, although it has been proved that phage synthesis is not affected at the enzymatic level (5).
Effects on Mammalian Viruses
In the last few years, many effects of rifamycins on mammalian virus growth have been reported. In contrast to the bacteria and their viruses, in which the action of the rifamycins is reasonably well understood, the effects on mammalian viruses are very heterogeneous and no general picture of the mechanism of action has yet emerged. It seems clear, however, that the action of the antibiotic on these viruses-is quite different from that on bacteria. To mention just two differences, only certain specific derivatives are markedly active, and very high concentrations of antibiotic are required to obtain any effects. It has not yet been possible, therefore, to employ the available derivatives for therapeutic purposes.
On the other hand, various rifamycin derivatives have proved to be very valuable tools for the elucidation of some biochemical events during virus development. Since quite divergent results are obtained, depending on the type of nucleic acid present in the virus, the various effects are discussed in two sections on DNA and RNA viruses.
Effects on DNA viruses The finding that poxvirus carries its own RNA polymerase (68, 109) prompted two groups of investigators (58, 157) to study the effect of rifamycins on the growth of this class of viruses in vitro. They found that high concentrations (100 yg/ml) of rifampin inhibited the growth of poxvirus but not of herpesvirus and pseudorabies virus. Furthermore, they showed that this activity was restricted to rifampin and that several other rifamycin derivatives with antibacterial activity were inactive. They were also able to select mutants of vaccinia virus that were resistant to rifampin and grew equally well in the presence of 100 ,ug of the antibiotic per ml.
Despite the numerous studies undertaken to find out how rifampin affects the multiplication of vaccinia virus, no definite answer to this question has emerged. Two periods of mRNA synthesis can be distinguished during virus replication: early and late mRNA. Neither is affected by rifampin, nor is the formation of viral DNA inhibited (12, 101, 106, 107) . Early and late proteins are also produced, although synthesis of the latter declines sooner than in the absence of the antibiotic (12, 106, 107, 158) , and some variations occur, depending on the virus strain (119, 163) . Rifampin does not inhibit the RNA polymerase activity of purified vaccinia virus particles (26, 101, 107, 158) . The only effect that could be detected was the lack of a particulate RNA polymerase activity, which appears late during virus infection in untreated cells (101) . However, mature virus particles are not formed in the presence of rifampin (51, 106) , but on removal of the antibiotic maturation to infective viruses can occur (106, 158) . This has been confirmed by electron microscope studies (51, 71, 110, 120) . Efforts have therefore been concentrated on the study of the events in virus development after the removal of rifampin. Moss and co-workers (106) found that even in the presence of cycloheximide, which inhibits protein synthesis, this maturation can occur. But Nagayama et al. (110) , using other inhibitors, have come to the conclusion that some RNA and protein synthesis is required for the final steps of virus assembly. These authors have shown that the synthesis of four defined enzymes that are found in the virus core was blocked by rifampin. In rifampin-resistant mutants, these enzymes were synthesized in a normal way. Pennington et al. (120) have also found that protein synthesis is necessary for the final maturation steps. Katz et al. the first event after the removal of rifampin was the conversion of the irregular membrane precursors to coated envelopes. This occurred during the first 10 min after rifampin removal, and only afterwards could the appearance of the late particulate RNA polymerase activity be demonstrated. The appearance of polymerase was nearly coincident with the formation of DNA-containing virus particles, which seems to indicate that integration into particulate form is required before this enzyme activity can be detected.
The development of cores within the envelopes could also be detected only after 30 to 60 min (69). Furthermore, Katz and Moss (69, 70) have found that rifampin prevents the formation of a core polypeptide by inhibiting the cleavage of a longer precursor mclecule. The function of this polypeptide is not yet known. The sequence of events after the removal of the antibiotic suggested that cleavage of the precursor occurs during the formation of the virus core. Rifampin seems to act by interrupting earlier maturational events that precede the formation of the core polypeptide.
Antiviral activity is restricted to rifampin and a few other hydrazone derivatives. Other rifamycins that are equally active on bacterial RNA polymerase (191) have no effect. Recently, it was found (124) that an unknown component of the streptovaricin complex (not streptovaricin A or C; see below) inhibited the growth of cowpox virus but was much less active against vaccinia or rabbit pox virus. The substituents of rifampin itself, 1-methyl-4-amino-piperazine (166) and other N-amino-piperazines (88) , were also reported to show antiviral activity. However, inhibition by 1-methyl-4-amino-piperazine could not be confirmed in recent studies by Follett and Pennington (38) . In bacteria, this substance has no effect (166); in fact, it has been shown that the ansa ring is the crucial part of the molecule for activity on bacterial RNA polymerase and that substituents in position 3 have practically no influence (177) . Which parts of the rifamycin molecule are responsible for the anti-poxvirus activity is not clear at present, but the molecular requirements for viral and bacterial inhibition are certainly not identical.
These differences, together with the fact that concentrations 1,000 to 10,000 times higher than are needed for bacterial inhibition are necessary to affect virus growth and that this inhibition is readily reversible, clearly show the different mode of action in bacteria and viruses. The large amounts of rifampin required naturally preclude any clinical application of the drug as an antiviral agent. It may be relevant in this respect that Engle et al. (36) found rifampin inactive in the mouse against vaccinia virus, even when administered to mice in maximally tolerated doses, whereas a partial inhibitory action of the drug was demonstrated in H-1 virus infections of hamsters.
Effects on RNA viruses Whereas some DNA viruses can be inhibited by rifampin, RNA viruses such as vesicular stomatitis virus and reovirus were not affected by the antibiotic (58, 157) . However, some in vitro effects on the class of oncogenic RNA viruses, such as Rous sarcoma virus have recently been found. Diggelmann and Weissmann (32) have shown that the formation of foci in chick fibroblast cell cultures infected with Rous sarcoma virus is inhibited by rifampin but not by other derivatives. As in the case of the DNA viruses, large concentrations of the drug are necessary to produce the effect. In the oncogenic RNA viruses, a new enzyme, an RNA-dependent DNA polymerase, has been identified (4, 155, 165) . A similar enzyme was also detected in the lymphoblasts of patients with acute lymphoblastic leukemia (46) . Whereas these enzymes are not or are only slightly inhibited by rifampin, N-desmethyl-rifampin was shown to be partially active at a concentration of 50 ,ug/ml. Much higher concentrations are required for complete inhibition (46) . Similar results have been reported by Green and co-workers for a variety of rifamycin derivatives with modified aminopiperazine side chains (52) .
If the presence of such an enzyme is indeed required for the proliferation of leukemic or other neoplastic cells, its specific inhibition would also be very interesting for possible clinical application. However, derivatives that are active in much smaller concentrations would be required. Moreover, recently a DNA polymerase was isolated from normal mammalian cells that was also inhibited by rifamycin derivatives (138) . A first hypothesis that this enzyme was closely related to the viral reverse transcriptases proved to be wrong, since it could be clearly distinguished from the viral enzyme by chromatographic and immunological methods (133a) . The fact that both enzymes, although physically different, are inhibited by rifamycins raises some doubt about the specificity of the action of rifamycins in this case.
Effects on Trachoma Agent
The infectious elementary bodies of trachoma agent belong to the Chlamydozoaceae which are considered unusually small bacterial cells. They contain DNA, RNA, and ribosomal subunits and grow as parasites in mammalian cells (134) .
Becker and co-workers (8) Rifamycins have a wide spectrum of antibacterial activity, but the susceptibility of the various organisms differs considerably. The minimal inhibitory concentration actually ranges from 0.0005 to over 20,4g/ml according to the bacterial species (76) . Particularly sensitive are gram-positive organisms and mycobacteria. Among the gram-negative organisms, Neisseria and Haemophilus are also quite sensitive, with minimal inhibitory concentrations of less than 1 jug/ml (1, 13) . Accordingly, the clinical efficacy of the orally active semisynthetic derivative rifampin (42) was proven to be greatest in infections caused by the most sensitive organisms. The antimycobacterial activity in vitro and in vivo has been well documented (22, 25, 94, 116) , and numerous publications on its clinical use as first line drug in tuberculosis have appeared (22, 29) .
Since about one organism in 108 spontaneously develops resistance to rifamycins (76, 82, 83) , the emergence of resistant bacteria is related to the inoculum size (60, 82) . As there is no cross-resistance with other antibiotics (83) , combination therapy in tuberculosis can be carried out with any other class of antibiotics (61) . Over 100 reports on the effect of rifampin against nontuberculous infections have been published (29) , the agent being most clearly defined in the treatment of gonorrhoea (182) , meningococcal carriers (27, 30) , and urinary (79, 121) , dermatological (102) , and respiratory infections (11) .
Besides its antibacterial activity, rifampin has a variety of effects on viruses, and it has even been referred to as "wonder drug." However, the term "drug" has to be used with caution when it is applied to the effects found with viruses and some forms of cancer. The quantities of the rifamycin derivatives thus far known that are needed for an inhibitory effect absolutely preclude any clinical use as systemic drug against viruses and cancer. The chief value of the rifamycins in these fields has thus far been as a tool in elucidating the biochemical events on which they have an influence. COMPOUNDS RELATED TO THE RIFAMYCINS Three groups of antibiotics that are chemically very similar to the rifamycins have been described: the streptovaricins (128, 130, 148, 181, 187) , the tolypomycins (67, 74, 75) , and geldanamycin (28, 135) . Like the rifamycins, they all contain an aromatic ring system spanned by an aliphatic bridge (Fig. 8) . Owing to this characteristic structure, the whole group of antibiotics has been termed ansamycins according to a proposition of V. Prelog.
The streptovaricins and tolypomycins have biochemical properties closely resembling those of the rifamycins, as would be expected from their chemical similarity. They inhibit the initiation step of bacterial RNA polymerase (103, 104) , although to a considerably lesser degree than the most active rifamycins. This is due to the fact that they form a less stable complex with RNA polymerase (Wehrli et al., in preparation). Both drugs competitively inhibit the binding of rifamycins to the enzyme, indicating that the binding site is the same for all three groups of antibiotics. Resistance to streptovaricins is also due to an altered RNA polymerase (114, 189, 190) .
However, mapping of the locus for streptovaricin resistance yields a result slightly different from that found with the rifamycins (189) . The available data are not sufficient to show whether this difference is real or an artifact due to experimental conditions, e.g., the use of different bacterial strains. But the fact that the streptovaricins compete with the rifamycins for a binding site on the enzyme, together with the finding that thus far no rifamycin-resistant RNA polymerase has been isolated that is inhibited by streptovaricin (16) , suggests that the two antibiotics attach to the enzyme at the same site.
Mammalian RNA polymerase has been shown to be unaffected by the streptovaricins (103) . However, streptovaricin D, but neither A nor B, inhibits the incorporation of nucleosides into HeLa cells (164) . One derivative of the streptovaricin complex (not A nor C) was found to inhibit the replication of poxvirus (124; see above). This selective activity corresponds to that of the rifamycins, in that only rifampin and a few other compounds affect viral growth.
Geldanamycin inhibits bacteria only in rather high concentrations (27) . No biochemical data have thus far been reported, but it is interesting to note that extensive simplification of the chromophoric ring system still yields a substance with antibiotic activities.
Another noteworthy compound is streptolydigin. It does not belong to the ansamycin group, and its mechanism of action is different. It also inhibits bacterial RNA polymerase, although it is not RNA chain initiation but the RNA chain elongation step that is affected (22a, 147) . Rather high concentrations of streptolydigin are needed to obtain inhibition. Resistance to this substance is due either to changes in cell permeability or to a modified RNA polymerase (136, 153) . In contrast to rifamycin, however, complete resistance to streptolydigin has not been observed. Heil and Zillig (57) have demonstrated that, like rifampin, it attaches to the ,3 subunit of RNA polymerase. Thus, marked similarities do exist between streptolydigin and the rifamycins, although their sites on the RNA polymerase are obviously not identical. However, comparison of the chemical structure of the two compounds reveals striking analogies ( Fig. 8 ): streptolydigin contains a great part of the ansa ring of the rifamycins, including the two oxygen functions at positions 21 and 23 and the tetragonal carbon atom 21, which has been shown to be crucial for the rifamycin activity. Thus, it could be maintained that the sites for streptolydigin and rifamycin on the RNA polymerase partly overlap and that a substituted carbon-hydrogen chain from C atom 15 to 27, such as is present in all the ansamycins and in streptolydigin, is a partial requirement for binding to RNA polymerase and thus for enzyme inhibition. However, it is clear that not every SUMMARY AND CONCLUSIONS The primary effect of the rifamycins on bacteria seems to be clear, at least in general: they specifically inhibit DNA-dependent RNA polymerase by blocking the RNA chain initiation step. The specificity of this action is due to the fact that the drug binds very tightly to the enzyme and therefore is effective at very low concentrations. Mutation of single amino acids in the enzyme can diminish or completely abolish this binding capacity, yielding a drug-resistant enzyme and consequently a resistant organism. The crucial part of the rifamycin molecule responsible for its inhibitory action on bacterial RNA polymerase is the ansa ring. The aromatic ring system, however, can be modified to some extent without detracting from the activity of the substance. Under conditions in which bacterial RNA polymerase is completely inhibited, the corresponding mammalian enzymes are not affected. Some rifamycin derivatives, especially the orally active derivative rifampin, have therefore proved to be clinically very valuable antibiotics.
Besides the specific inhibition of bacterial DNAdependent RNA polymerase, the rifamycins display a variety of other effects. These other actions, however, require a 100-to 10,000-fold higher concentration of the antibiotic. All results must, therefore, be very carefully evaluated to exclude possible unspecific reactions. This applies especially to the various observations made with eukaryotic cells, for example, those with mitochondria and chloroplasts. These have usually been explained, by analogy with bacteria, as being due to inhibition of RNA polymerase. However, in most instances the enzymes were not well defined. In the case of yeast, it was possible to isolate and characterize-two mitochondrial RNA polymerases that were DNA-dependent, but neither enzyme was inhibited by rifampin concentrations 1,000 times higher than those required to inhibit the bacterial enzyme (170) . Thus, it is clear that mitochondrial RNA polymerase is not as bacteria-like as it has often been asserted to be.
The effects of the rifamycins on viruses are rather heterogeneous. In the case of bacterial viruses, the drug has mainly been used to determine the role played by the host RNA polymerase during virus development. Mammalian viruses are, in general, unlikely to be influenced by rifamycins. However, the multiplication of poxviruses has been shown to be sensitive to D STAEHELIN BACTERIOL. REV. certain rifamycin derivatives, especially rifampin. Although very high concentrations of antibiotic are needed, the effect is specific, since rifampinresistant strains could be selected. The mechanism of action is not clear as yet; however, it seems to be different from that observed in bacteria.
Most recently, the observation that selected rifamycin derivatives affect the RNA-dependent DNA polymerase found in tumor-inducing RNA viruses and in leukemic cells has led to speculations on the possibility that some forms of cancer might be affected by the rifamycins. However, the very large amounts of antibiotic required to produce enzyme inhibition rule out the therapeutic use of any of the known derivatives. Furthermore, the recent discovery in normal mammalian cells of an enzyme different from the one found in RNA viruses but also inhibited by certain rifamycins (133a, 138) raises some doubt about the specificity of the effects on the viral enzyme. 
